Back to top
more

Fulcrum Therapeutics (FULC)

(Delayed Data from NSDQ)

$7.14 USD

7.14
261,291

+0.01 (0.14%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $7.12 -0.02 (-0.28%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 9.09% and 34%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics

by Zacks Equity Research

Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics are part of the Zacks top Analyst Blog.

Biotech Stock Roundup: REGN Up on Approval, APLS, NVAX Gain on Updates & More

by Zacks Equity Research

Regulatory updates from Regeneron (REGN) and Apellis (APLS) are in focus in the biotech sector.

Fulcrum (FULC) Up as FDA Lifts Clinical Hold on SCD Candidate

by Zacks Equity Research

Fulcrum's (FULC) shares surge as the FDA lifts the clinical hold it had earlier placed on its pipeline candidate FTX-6058, to treat patients with sickle cell disease.

Fulcrum Therapeutics, Inc. (FULC) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 13.64% and 45.10%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Fulcrum Therapeutics, Inc. (FULC) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 12.77% and 82.95%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Equillium, Inc. (EQ) delivered earnings and revenue surprises of 45% and 21.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of -2.04% and 64.29%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Bionano Genomics, Inc. (BNGO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Bionano Genomics, Inc. (BNGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Fulcrum Therapeutics, Inc. (FULC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

by Zacks Equity Research

Fulcrum Therapeutics, Inc. (FULC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street Analysts Think Fulcrum Therapeutics, Inc. (FULC) Could Surge 71.81%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Fulcrum Therapeutics, Inc. (FULC) points to a 71.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Atara Biotherapeutics (ATRA) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -18.03% and 99.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Qiagen (QGEN) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Qiagen (QGEN) delivered earnings and revenue surprises of 12.77% and 3.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Are You Looking for a Top Momentum Pick? Why Fulcrum Therapeutics, Inc. (FULC) is a Great Choice

by Zacks Equity Research

Does Fulcrum Therapeutics, Inc. (FULC) have what it takes to be a top stock pick for momentum investors? Let's find out.

Wall Street Analysts Believe Fulcrum Therapeutics, Inc. (FULC) Could Rally 73.02%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Fulcrum Therapeutics, Inc. (FULC) points to a 73% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Strength Seen in Fulcrum Therapeutics, Inc. (FULC): Can Its 20.6% Jump Turn into More Strength?

by Zacks Equity Research

Fulcrum Therapeutics, Inc. (FULC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Can Fulcrum Therapeutics, Inc. (FULC) Climb 232% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Fulcrum Therapeutics, Inc. (FULC) points to a 232.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Fulcrum Therapeutics, Inc. (FULC) Have the Potential to Rally 232% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 232.3% upside potential for Fulcrum Therapeutics, Inc. (FULC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Fulcrum Therapeutics, Inc. (FULC) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 19.35% and 45.86%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Horizon Therapeutics (HZNP) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 25% and 4.10%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Dr. Reddy's (RDY) Earnings & Revenues Trump Estimates in Q2

by Zacks Equity Research

Dr. Reddy's (RDY) earnings and sales beat estimates in second-quarter fiscal 2023.

Fulcrum Therapeutics, Inc. (FULC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Fulcrum Therapeutics, Inc. (FULC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why Fulcrum Therapeutics, Inc. (FULC) is Poised for a Turnaround After Losing 32.6% in 4 Weeks

by Zacks Equity Research

Fulcrum Therapeutics, Inc. (FULC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Fulcrum Therapeutics, Inc. (FULC) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of -25.76% and 28.98%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Immuneering Corporation (IMRX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Immuneering Corporation (IMRX) delivered earnings and revenue surprises of 15.38% and 65.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?